《公司業績》醫思健康(02138.HK)半年純利665.1萬元跌91.7% 派中期息0.5仙
醫思健康(02138.HK)公布截至今年9月底止中期業績,營業額21.21億元,按年升12%。純利665.1萬元,按年跌91.7%;每股盈利0.6仙。派中期息0.5仙,上年同期派5.8仙。
公司指,收入增長主要受年初香港及內地之間恢復跨境旅遊,吸引內地遊客逐漸回流所帶動。盈利下跌因為來自香港政府保就業計劃的補貼減少約4,340萬元、新設立服務點的營運槓桿暫時較低、通脹導致成本上升、折舊及攤銷開支增加、利率上升導致銀行借款利息開支增加約1,700萬元所致。(cy/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.